RUNX2 and acute myeloid leukemia: In agreement with the qPCR result, a clear increase of the p50 binding activity after CIGB-300 treatment was confirmed by ELISA assay in both AML cell lines; although a higher level of p50 DNA binding was observed after OCI-AML3 cells were treated with CIGB-300 for 2 h and 5 h, compared to HL-60 (Fig. 7A).qPCR results also evidenced TNFA(TNF-α) was up-regulated by CIGB-300 3.8- fold in OCI-AML3 and 11.6- fold in HL-60 as early as 30 min of drug exposure.